Literature DB >> 24019546

Long-term outcomes after pelvic radiation for early-stage endometrial cancer.

Mathias Onsrud1, Milada Cvancarova, Taran P Hellebust, Claes G Tropé, Gunnar B Kristensen, Kristina Lindemann.   

Abstract

PURPOSE: This follow-up of a randomized study was conducted to assess the long-term effects of external beam radiation therapy (EBRT) in the adjuvant treatment of early-stage endometrial cancer. PATIENTS AND METHODS: Between 1968 and 1974, 568 patients with stage I endometrial cancer were included. After primary surgery, patients were randomly assigned to either vaginal radium brachytherapy followed by EBRT (n = 288) or brachytherapy alone (n = 280). Overall survival was analyzed by using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate hazard ratios (HRs) with 95% CIs. We also conducted analyses stratified by age groups.
RESULTS: After median 20.5 years (range, 0 to 43.4 years) of follow-up, no statistically significant difference was revealed in overall survival (P = .186) between treatment groups. However, women younger than age 60 years had significantly higher mortality rates after EBRT (HR, 1.36; 95% CI, 1.06 to 1.76) than the control group. The risk of secondary cancer increased after EBRT, especially in women younger than age 60 years (HR, 2.02; 95% CI, 1.30 to 3.15).
CONCLUSION: We observed no survival benefit of external pelvic radiation in early-stage endometrial carcinoma. In women younger than age 60 years, pelvic radiation decreased survival and increased the risk of secondary cancer. Adjuvant EBRT should be used with caution, especially in women with a long life expectancy.

Entities:  

Mesh:

Year:  2013        PMID: 24019546     DOI: 10.1200/JCO.2013.48.8023

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

1.  The association between histological subtype of a first primary endometrial cancer and second cancer risk.

Authors:  Jennifer Rhoades; Monica Hagan Vetter; James L Fisher; David E Cohn; Ritu Salani; Ashley S Felix
Journal:  Int J Gynecol Cancer       Date:  2018-12-21       Impact factor: 3.437

2.  Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.

Authors:  Sean Soisson; Patricia A Ganz; David Gaffney; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Mike Newman; Alison Fraser; Ken Smith; Kimberly Herget; Heidi A Hanson; Yelena P Wu; Joseph Stanford; Theresa L Werner; Veronica Wendy Setiawan; Mia Hashibe
Journal:  Gynecol Oncol       Date:  2017-12-27       Impact factor: 5.482

3.  Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?

Authors:  Abdurrahman Hamdi İnan; Gülçin Şahin Ersoy; Yusuf Yıldırım; Tutku Gürbüz; Ayşe Gül Kebapçılar; Merih Hanhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-07-14

Review 4.  Functional Changes of the Genitourinary and Gastrointestinal Systems before and after the Treatment of Endometrial Cancer-A Systematic Review.

Authors:  Marcin Oplawski; Agata Średnicka; Aleksandra Dutka; Sabina Tim; Agnieszka Mazur-Bialy
Journal:  J Clin Med       Date:  2021-11-27       Impact factor: 4.241

5.  Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.

Authors:  Ji-Yeon Yang; Henrica M J Werner; Jie Li; Shannon N Westin; Yiling Lu; Mari K Halle; Jone Trovik; Helga B Salvesen; Gordon B Mills; Han Liang
Journal:  Clin Cancer Res       Date:  2015-07-29       Impact factor: 12.531

Review 6.  Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma.

Authors:  J Stubert; B Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

7.  Risk and prognosis of secondary bladder cancer after post-operative radiotherapy for gynecological cancer.

Authors:  Li Wen; Guansheng Zhong; Yingjiao Zhang; Miaochun Zhong
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

Review 8.  Adjuvant therapy for endometrial cancer.

Authors:  Maria C Deleon; Natraj R Ammakkanavar; Daniela Matei
Journal:  J Gynecol Oncol       Date:  2014-04-09       Impact factor: 4.401

Review 9.  Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer.

Authors:  Sarah M Temkin; Edward J Tanner; Summer B Dewdney; Lori M Minasian
Journal:  Front Oncol       Date:  2016-05-09       Impact factor: 6.244

10.  Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer.

Authors:  Lucas Gomes Sapienza; Antonio Aiza; Maria José Leite Gomes; Michael Jenwei Chen; Antonio Cassio de Assis Pellizzon; David B Mansur; Glauco Baiocchi
Journal:  J Contemp Brachytherapy       Date:  2015-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.